STOCK TITAN

MediWound Ltd - MDWD STOCK NEWS

Welcome to our dedicated news page for MediWound (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on MediWound.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MediWound's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MediWound's position in the market.

Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) to release Q3 2023 financial results on November 21, 2023. The company will host a conference call and webcast to discuss the results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences earnings
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announced a positive opinion from the European Medicines Agency recommending a label expansion for NexoBrid to include all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns. This expansion is based on the results of a global Phase 3 trial and additional pediatric data, confirming NexoBrid's safety and efficacy. The expansion is expected to redefine the standard of care for severe burns and significantly increase the company's addressable market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) and PolyMedics Innovations (PMI) have announced a collaboration to promote NexoBrid® in Germany, Austria, Belgium, the Netherlands, and Luxemburg. NexoBrid, a non-surgical solution for eschar removal in burns, complements PMI's existing product line, allowing for a comprehensive solution for burn patients. The agreement aims to drive increased utilization of NexoBrid in the specified regions, leveraging PMI's customer access and commercial resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
Rhea-AI Summary
MediWound collaborates with 3M Health Care for a pivotal study on venous leg ulcers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary
MediWound addresses emergency demand for NexoBrid to treat burn casualties
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary
MediWound receives additional funding of $6.5 million from the U.S. Department of Defense to develop NexoBrid as a non-surgical burn treatment solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
Rhea-AI Summary
MediWound announces U.S. commercial availability of NexoBrid for eschar removal in burn patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
MediWound successfully participated in the 20th European Burns Association Congress, featuring NexoBrid in 20 scientific presentations. The event showcased NexoBrid's application in various burn care scenarios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
-
Rhea-AI Summary
MediWound Ltd. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announced progress on EscharEx Phase III study protocol, two key research collaborations, and financial results. The company also provided a corporate update, including a cash balance of $51.3 million and a conference call on August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
MediWound Ltd

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

151.77M
5.02M
25.73%
33.91%
1.71%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
42 Hayarkon Street

About MDWD

mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and